1. Home
  2. AACG vs RNTX Comparison

AACG vs RNTX Comparison

Compare AACG & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AACG
  • RNTX
  • Stock Information
  • Founded
  • AACG 1999
  • RNTX 2001
  • Country
  • AACG China
  • RNTX United States
  • Employees
  • AACG N/A
  • RNTX N/A
  • Industry
  • AACG Other Consumer Services
  • RNTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • AACG Real Estate
  • RNTX Health Care
  • Exchange
  • AACG Nasdaq
  • RNTX Nasdaq
  • Market Cap
  • AACG 24.4M
  • RNTX 26.5M
  • IPO Year
  • AACG N/A
  • RNTX N/A
  • Fundamental
  • Price
  • AACG $2.04
  • RNTX $1.35
  • Analyst Decision
  • AACG
  • RNTX Hold
  • Analyst Count
  • AACG 0
  • RNTX 1
  • Target Price
  • AACG N/A
  • RNTX N/A
  • AVG Volume (30 Days)
  • AACG 105.0K
  • RNTX 114.6K
  • Earning Date
  • AACG 11-06-2025
  • RNTX 08-14-2025
  • Dividend Yield
  • AACG N/A
  • RNTX N/A
  • EPS Growth
  • AACG N/A
  • RNTX N/A
  • EPS
  • AACG N/A
  • RNTX N/A
  • Revenue
  • AACG $39,064,701.00
  • RNTX N/A
  • Revenue This Year
  • AACG N/A
  • RNTX N/A
  • Revenue Next Year
  • AACG N/A
  • RNTX N/A
  • P/E Ratio
  • AACG N/A
  • RNTX N/A
  • Revenue Growth
  • AACG 15.19
  • RNTX N/A
  • 52 Week Low
  • AACG $0.50
  • RNTX $1.04
  • 52 Week High
  • AACG $2.30
  • RNTX $4.40
  • Technical
  • Relative Strength Index (RSI)
  • AACG 56.34
  • RNTX 55.32
  • Support Level
  • AACG $1.77
  • RNTX $1.06
  • Resistance Level
  • AACG $2.25
  • RNTX $1.48
  • Average True Range (ATR)
  • AACG 0.23
  • RNTX 0.13
  • MACD
  • AACG -0.01
  • RNTX 0.04
  • Stochastic Oscillator
  • AACG 64.19
  • RNTX 68.72

About AACG ATA Creativity Global

ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments of the company are (i) Overseas art study services (ii) Other educational services and (iii) Other services. Majority of its revenue comes from Overseas art study services.

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: